{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T09:13:47Z","timestamp":1790241227151,"version":"4.1.0"},"reference-count":36,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer AG","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Bayer SpA"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>Nonadherence to direct oral anticoagulant (DOAC) therapy exposes patients with nonvalvular atrial fibrillation (NVAF) to an increased risk of ischemic stroke and systemic embolism. Nevertheless, approximately 20% of patients discontinue treatment within the first year. In Italy, data on DOAC discontinuation rates are limited, especially in high-risk populations. RITMUS-AF, a prospective, observational cohort study conducted in 31 centers across Italy, investigated rivaroxaban treatment discontinuation in patients with NVAF in routine clinical practice. It included 805 patients aged \u226518 years with NVAF who were newly initiated on rivaroxaban. The primary endpoint was the proportion of patients who discontinued treatment during a 24-month follow-up. Secondary endpoints included the reasons for discontinuation and self-reported adherence to rivaroxaban therapy. At baseline, most patients were oral anticoagulant (OAC)-na\u00efve (n\u2009=\u2009599, 74.4%) and had either symptomatic (n\u2009=\u2009364, 45.2%) or asymptomatic (n\u2009=\u2009441, 54.8%) NVAF. The overall rate of rivaroxaban discontinuation was 8.9 per 100 patient-years (95% CI: 7.1\u201311.0). The main reasons for discontinuation were adverse events or physician decisions. After 24 months, high adherence was reported in 90.9% of OAC-non-na\u00efve patients and 61.5% of OAC-na\u00efve patients. Forty-six patients (5.7%) experienced bleeding events (with major bleeding events occurring in &lt;0.5% of cases), and one patient (0.1%) had an ischemic stroke. In the RITMUS-AF study, rivaroxaban treatment was associated with a low treatment discontinuation rate, along with high self-reported adherence and a relatively low incidence of ischemic stroke and bleeding events in a high-risk population, findings that may help inform clinical decision-making on the use of rivaroxaban in routine practice.<\/jats:p>","DOI":"10.1371\/journal.pone.0341633","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T18:31:11Z","timestamp":1770921071000},"page":"e0341633","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Rivaroxaban treatment discontinuation rates in patients with nonvalvular atrial fibrillation in Italian clinical practice: RITMUS-AF"],"prefix":"10.1371","volume":"21","author":[{"given":"Carmine","family":"Pizzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1927-244X","authenticated-orcid":true,"given":"Leopoldo","family":"Pagliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca Dalle","family":"Carbonare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piergiuseppe","family":"Agostoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egidio","family":"Imbalzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gennaro","family":"Galasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianni","family":"Casella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicol\u00f2","family":"Dasseni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"De Luca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Italo","family":"Porto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9028-7169","authenticated-orcid":true,"given":"Biagio","family":"Sassone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Tosarello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pareen","family":"Vora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Erminero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni Battista","family":"Forleo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Fusco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciro","family":"Mauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Milone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9324-466X","authenticated-orcid":true,"given":"Gian Piero","family":"Perna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"issue":"5","key":"pone.0341633.ref001","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1016\/j.ijcard.2012.12.093","article-title":"Atrial fibrillation: profile and burden of an evolving epidemic in the 21st century","volume":"167","author":"J Ball","year":"2013","journal-title":"Int J Cardiol"},{"issue":"8","key":"pone.0341633.ref002","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1161\/CIRCULATIONAHA.113.005119","article-title":"Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study","volume":"129","author":"SS Chugh","year":"2014","journal-title":"Circulation"},{"issue":"10","key":"pone.0341633.ref003","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1093\/europace\/euz141","article-title":"Prevalence of atrial fibrillation in the Italian elderly population and projections from 2020 to 2060 for Italy and the European Union: the FAI Project","volume":"21","author":"A Di Carlo","year":"2019","journal-title":"Europace"},{"issue":"11","key":"pone.0341633.ref004","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1111\/jgs.16748","article-title":"Prevalence of Atrial Fibrillation Subtypes in Italy and Projections to 2060 for Italy and Europe","volume":"68","author":"A Di Carlo","year":"2020","journal-title":"J Am Geriatr Soc"},{"issue":"12","key":"pone.0341633.ref005","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1093\/europace\/euu178","article-title":"The definition of valvular and non-valvular atrial fibrillation: results of a physicians\u2019 survey","volume":"16","author":"M Molteni","year":"2014","journal-title":"Europace"},{"key":"pone.0341633.ref006","article-title":"Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis","volume":"354","author":"A Odutayo","year":"2016","journal-title":"BMJ"},{"issue":"36","key":"pone.0341633.ref007","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"IC Van Gelder","year":"2024","journal-title":"Eur Heart J"},{"issue":"12","key":"pone.0341633.ref008","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"SJ Connolly","year":"2009","journal-title":"N Engl J Med"},{"issue":"22","key":"pone.0341633.ref009","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"RP Giugliano","year":"2013","journal-title":"N Engl J Med"},{"issue":"11","key":"pone.0341633.ref010","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"CB Granger","year":"2011","journal-title":"N Engl J Med"},{"issue":"10","key":"pone.0341633.ref011","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"MR Patel","year":"2011","journal-title":"N Engl J Med"},{"issue":"4","key":"pone.0341633.ref012","doi-asserted-by":"crossref","first-page":"304","DOI":"10.4065\/mcp.2010.0575","article-title":"Medication adherence: WHO cares?","volume":"86","author":"MT Brown","year":"2011","journal-title":"Mayo Clin Proc"},{"issue":"7","key":"pone.0341633.ref013","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1160\/TH16-12-0961","article-title":"Cessation of oral anticoagulation is an important risk factor for stroke and mortality in atrial fibrillation patients","volume":"117","author":"JM Rivera-Caravaca","year":"2017","journal-title":"Thromb Haemost"},{"issue":"9","key":"pone.0341633.ref014","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1111\/j.1468-1331.2011.03363.x","article-title":"Effect of warfarin withdrawal on thrombolytic treatment in patients with ischaemic stroke","volume":"18","author":"YD Kim","year":"2011","journal-title":"Eur J Neurol"},{"issue":"2","key":"pone.0341633.ref015","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1046\/j.1365-2141.1996.d01-1499.x","article-title":"Rebound after cessation of oral anticoagulant therapy: the biochemical evidence","volume":"92","author":"U Genewein","year":"1996","journal-title":"Br J Haematol"},{"issue":"9","key":"pone.0341633.ref016","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1111\/jth.15415","article-title":"Risks associated with discontinuation of oral anticoagulation in newly diagnosed patients with atrial fibrillation: results from the GARFIELD-AF Registry","volume":"19","author":"F Cools","year":"2021","journal-title":"J Thromb Haemost"},{"key":"pone.0341633.ref017","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ahj.2020.04.016","article-title":"Discontinuation rates of warfarin versus direct acting oral anticoagulants in US clinical practice: results from Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II)","volume":"226","author":"LR Jackson","year":"2020","journal-title":"Am Heart J"},{"issue":"10","key":"pone.0341633.ref018","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"23","author":"J Steffel","year":"2021","journal-title":"Europace"},{"issue":"5","key":"pone.0341633.ref019","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1161\/CIRCOUTCOMES.113.000192","article-title":"Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin","volume":"6","author":"M Zalesak","year":"2013","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"2","key":"pone.0341633.ref020","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1136\/heartjnl-2019-315307","article-title":"Adherence and persistence to direct oral anticoagulants in atrial fibrillation: a population-based study","volume":"106","author":"A Banerjee","year":"2020","journal-title":"Heart"},{"issue":"3","key":"pone.0341633.ref021","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00228-015-1983-z","article-title":"Comparison of treatment persistence with different oral anticoagulants in patients with atrial fibrillation","volume":"72","author":"T Forslund","year":"2016","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"pone.0341633.ref022","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/jth.12845","article-title":"Dabigatran adherence in atrial fibrillation patients during the first year after diagnosis: a nationwide cohort study","volume":"13","author":"A Gorst-Rasmussen","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"10","key":"pone.0341633.ref023","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-031342","article-title":"Discontinuation of non-Vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation: a population-based cohort study using primary care data from The Health Improvement Network in the UK","volume":"9","author":"A Ruig\u00f3mez","year":"2019","journal-title":"BMJ Open"},{"issue":"14","key":"pone.0341633.ref024","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1093\/eurheartj\/ehv466","article-title":"XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation","volume":"37","author":"AJ Camm","year":"2016","journal-title":"Eur Heart J"},{"issue":"4","key":"pone.0341633.ref025","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1093\/europace\/euu319","article-title":"Drug persistence with rivaroxaban therapy in atrial fibrillation patients-results from the Dresden non-interventional oral anticoagulation registry","volume":"17","author":"J Beyer-Westendorf","year":"2015","journal-title":"Europace"},{"key":"pone.0341633.ref026","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2147\/VHRM.S216749","article-title":"Clinical characteristics and health care resources in patients treated with oral anticoagulants: evidences from italian administrative databases","volume":"15","author":"L Degli Esposti","year":"2019","journal-title":"Vasc Health Risk Manag"},{"issue":"6","key":"pone.0341633.ref027","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2018.12.036","article-title":"Net clinical benefit of non-vitamin K antagonist vs vitamin K antagonist anticoagulants in elderly patients with atrial fibrillation","volume":"132","author":"G Patti","year":"2019","journal-title":"Am J Med"},{"key":"pone.0341633.ref028","first-page":"101229","article-title":"Persistence to rivaroxaban therapy for stroke prevention in clinical practice in Italy: Rationale and design of the RITMUS-AF prospective observational cohort study","volume":"47","author":"G Piero Perna","year":"2023","journal-title":"Int J Cardiol Heart Vasc"},{"key":"pone.0341633.ref029","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ijcard.2017.01.098","article-title":"Permanent discontinuation of non vitamin K oral anticoagulants in real life patients with non-valvular atrial fibrillation","volume":"236","author":"MC Vedovati","year":"2017","journal-title":"Int J Cardiol"},{"issue":"2","key":"pone.0341633.ref030","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1161\/CIRCULATIONAHA.113.005008","article-title":"Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)","volume":"130","author":"JL Halperin","year":"2014","journal-title":"Circulation"},{"issue":"1","key":"pone.0341633.ref031","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11239-023-02797-8","article-title":"Direct oral anticoagulants: patient reported adherence and minor bleedings","volume":"56","author":"A Hayat","year":"2023","journal-title":"J Thromb Thrombolysis"},{"issue":"3","key":"pone.0341633.ref032","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1080\/00015385.2021.1908702","article-title":"Direct oral anticoagulants and therapeutic adherence: do not let your guard down","volume":"77","author":"L Di Gennaro","year":"2022","journal-title":"Acta Cardiol"},{"issue":"1","key":"pone.0341633.ref033","first-page":"7","article-title":"Assessment of patient adherence to direct oral anticoagulant vs warfarin therapy","volume":"117","author":"SI Patel","year":"2017","journal-title":"JOM"},{"issue":"1","key":"pone.0341633.ref034","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s00228-022-03418-8","article-title":"Self-reported adherence to direct oral anticoagulants versus warfarin therapy in a specialized thrombosis service-a cross-sectional study of patients in a Canadian Health Region","volume":"79","author":"KO Bonsu","year":"2023","journal-title":"Eur J Clin Pharmacol"},{"issue":"10","key":"pone.0341633.ref035","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1185\/03007995.2015.1074064","article-title":"Medication persistence and discontinuation of rivaroxaban and dabigatran etexilate among patients with non-valvular atrial fibrillation","volume":"31","author":"WW Nelson","year":"2015","journal-title":"Curr Med Res Opin"},{"key":"pone.0341633.ref036","article-title":"Piani terapeutici dei farmaci: quanti e quali? fotografia di uno strumento di appropriatezza prescrittiva e assistenziale","author":"C Piccinni","year":"2021","journal-title":"Recenti Prog Med"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0341633","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T18:31:17Z","timestamp":1770921077000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0341633"}},"subtitle":[],"editor":[{"given":"Roberto Magalh\u00e3es","family":"Saraiva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":36,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,12]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0341633","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,12]]}}}